VOLITIONRX LTD 8-K

What Happened
VOLITIONRX LTD (VNRX) filed an 8-K reporting that on June 7, 2026 it entered a securities purchase agreement and completed a public offering that closed June 9, 2026. The Offering sold 2,960,000 shares of common stock with accompanying warrants to purchase 1,480,000 shares at a combined price of $1.55 per share and warrant. Net proceeds to the company were approximately $4.1 million (excludes any proceeds from future warrant exercises).

Key Details

• Offering size and price: 2,960,000 common shares and warrants to buy 1,480,000 shares; $1.55 combined offering price per share & warrant.
• Warrants: $1.55 exercise price, exercisable immediately, five-year term; cashless exercise only if underlying shares are not registered or prospectus unavailable.
• Ownership limits: Warrant exercises are restricted so a holder (and affiliates) cannot exceed 4.99% (or 9.99% if elected) of outstanding common stock upon exercise. Pre‑funded warrants were offered for buyers who would otherwise exceed the threshold, but none were sold.
• Proceeds and use: ~ $4.1M net proceeds after fees and expenses; additional gross proceeds if all warrants exercised on a cash basis would be ~ $2.3M. Company plans to use funds for research/product development, clinical studies, commercialization, working capital and repayment of certain secured convertible notes.
• Placement agent and administrative items: Maxim Group LLC acted as placement agent (company reimbursed $75,000 of expenses); VStock Transfer, LLC will act as warrant agent. Legal opinion from Stradling Yocca Carlson & Rauth LLP was filed.

Why It Matters
This filing confirms VolitionRx raised immediate liquidity of about $4.1M and has potential to raise another ~$2.3M if warrants are exercised. For investors, the transaction is dilutive to existing shareholders (common shares issued plus potential warrant conversion), though warrant exercises are limited by ownership caps to prevent large single‑holder concentration. The proceeds are earmarked for R&D, clinical work, commercialization and partial debt repayment, which could support the company’s clinical and product development timelines.